Summary. Many of the profound effects of staphylococcal septicaemia are thought to be the result of entry of enterotoxins into the systemic circulation. The aim of this study was to investigate the disposition of staphylococcal enterotoxin A (SEA) in the rat and its possible removal from blood. SEA labelled with 1251 was administered intravenously (250 pg/kg) to rats. The blood clearance of SEA showed a biphasic pattern; an initial fast disappearance (half-life c. 3 min) was followed by a slower one (half-life c. 2 h). Thirty minutes after injection of 1251-labelled SEA, most of the radioactivity was concentrated in the kidneys, indicating that renal excretion was the main route of elimination of SEA. The adsorption capacities of polymer-coated activated charcoal (DHP-1 and Adsorba 1 50C), uncharged resin (Amberlite XAD-7), anion exchange resin (Dowex-I) and polymyxin B matrix were assessed by measurement of the equilibrium adsorption isotherms for SEA. DHP-1 charcoal, Amberlite XAD-7 resin and Dowex-1 resin adsorbed similar amounts of SEA in human plasma. Plasma perfusion experiments were performed in vitro with small columns containing either charcoal or resin adsorbents. Over 4 h perfusion, DHP-1 charcoal removed 50 YO of the initial amount of 1251-SEA, Adsorba 150C charcoal 8.1 YO of SEA and Amberlite XAD-7 resin 32.5 YO of SEA. These results suggest that it may be feasible to develop the adsorbent columns for direct removal of SEA from the plasma of patients with staphylococcal septicaemia.
Introduction
The exotoxins released by Staphylococcus aureus include enterotoxins (SEs) A, B, Cl-3, D and E, toxic shock syndrome toxin 1 (TSST-1) and staphylococcal exfoliative toxin (ExFt). These toxins are structurally closely and are known to be responsible for human diseases such as food p~isoning,~ shock4 and scalded skin ~yndrome.~ In mice and monkeys, these toxins produce rapid weight loss and death.6* ' Staphylococcal sepsis in man could cause potent enterotoxins to circulate throughout the body, resulting in damaging effects. Studies have been performed in animals to characterise the toxaemia produced by parenteral administration of staphylococcal enterotoxins. Intravenous administration of SEB produced fever and leucopenia followed by leucocytosis and shock.' Shock appeared to develop through pathophysiological mechanisms similar to those which accompany bacterial endot~xaemia,~ which is mediated by cytokines released from macrophages or monocytes as a result of stimulation by lipopolysaccharide (LPS).". '' The staphylococcal toxins also increase susceptibility to endotoxic shock,I2 which may be important clinically. The specific mechanisms involved in the toxicity of staphylococcal enterotoxin A (SEA) have been elucidated only recently, in studies which have demonstrated that nearly all of the toxins bind to major histocompati bili ty complex (MHC) proteins. 1 3 3 l4 These complexes of toxin and MHC proteins stimulate T cell^,'^.^^ causing the release of large amounts of cytokines, including tumour necrosis factor (TNF) and y-interferon (IFN-y).177 l8 These responses are beneficial to the host in small quantities, but damaging in excess. Direct removal of these enterotoxins from the circulation may be of potential therapeutic value in preventing the consequences of staphylococcal septicaemia.
In the present study, the clearance and tissue distribution of SEA was investigated in rats and the capacities of various adsorbents to bind this toxin in vitro assessed with the aim of directly removing the toxin from the circulation. Male Wistar rats (190-200 g) were housed in an airconditioned room with a 12-h light-dark cycle and maintained on a commercial stock diet and tap water ad libitum. For experiments in vitro, SEA was added to citrated human plasma, obtained from four patients with haemochromatosis who were undergoing weekly venesection therapy and who all had normal serum tests of liver function.
Materials and methods

Iodination of SEA
SEA was radiolabelled with carrier-free Na1251 by immobilised lactoperoxidase according to the method of David and Rei~fe1d.l~ Briefly, 100 pg of SEA in 50 pl of pyrogen-free water was mixed with 50 pl of azide-free phosphate-buffered saline (PBS), pH 7-4, lop1 of 0.1 mM NaI, 25pl of immobilised lactoperoxidase suspension and 10 pl(1 mCi) of carrier-free Na1251. The reaction was started by the addition of 10 pl of 1 mM H,02 and incubation was for 30 min at room temperature. The reaction was terminated by diluting the mixture to 0.5 ml with PBS containing sodium azide 0.02 %, and the lactoperoxidase was removed by centrifugation at 3500 g for 3 min. Radiolabelled SEA was separated from the NaI by fractionation on a Sephadex G-50 column and purified by extensive dialysis with PBS. The concentration of SEA was determined by an ELISA specific for SEA with a sensitivity limit of 7.8 ng/ml. This sandwich assay incorporated a guinea-pig polyclonal antibody to SEA on the plate and a rabbit polyclonal second antibody to SEA, both provided by the Centre for Applied Microbiology and Research; detection was with antibody to rabbit IgG conjugated with horseradish peroxidase (Dako). The specific activity of 1251-SEA was 220 Ci/mmol.
1251-SEA administration to rats
SEA (50 pg containing 2.25 pCi of 1251-labelled SEA in 200 pl of PBS) was injected as a bolus into the femoral vein of the rats (n = 9) over a period of 1 min. Rats were kept anaesthetised throughout the experiment with sodium pentobarbitone. Clearance of SEA was determined from the radioactivity in 100-pl blood samples taken at various intervals, starting at 2min after injection (three rats were sampled at each time point). Distribution of SEA in tissues was studied in rats killed 5, 30 or 120 min after injection. Whole organs were weighed, and blood, urine and tissue samples were placed into pre-weighed labelled vials, and sample weights were determined. Tissue, blood or urine samples were distributed into plastic tubes and the radioactivity was measured in a y scintillation counter (Canberra Packard). The total amount of SEA in pgfg of tissue was calculated from 1251 cpm/g of tissue and the specific activity of the injected SEA. To determine free iodine in blood and urine samples, membrane ultrafiltration was performed in an Amicon Stirred Cell (Amicon Ltd, Upper Mill, Stonehouse) with a PMlO membrane (10000 da cut off) as the M, of SEA protein is 27 078. Free 1251 present passes through the membrane and is detected in the filtrate.
In vitro binding of SEA
The two polymer-coated activated charcoals (DHP-1, Adsorba 150C), uncharged resin (Amberlite XAD-7), anion exchange resin (Dowex-1) and polymyxin matrix (Affi-Prep) were tested for their capacities to bind 1251-labelled SEA in vitro. To determine the effects of plasma protein binding of SEA on adsorption, two different media were used: PBS, pH 7.4, with bovine serum albumin (BSA) 1 mg/ml (to prevent adhesion to plastic) and human plasma; 1 g (wet weight) of the charcoals or resin, or 1 ml of polymyxin matrix (50 YO suspension) was added to 5 ml of the media containing 1251-SEA at a concentration of 1, 5, 10, 50, 100, 500 or 1000 ng/ml, and mixed on a roller mixer for 48 h at 4°C. The supernate was aspirated and assayed for free SEA by measurement of y radioactivity. A sample of the wet charcoal and resin used was dried at 60°C to obtain the dry weights of adsorbent used. The binding capacity of each adsorbent was determined from the amount of SEA bound/g of dry adsorbent at equilibrium.
Adsorption characteristics during column perfusion
Columns (7.2 cm length, 2.2 cm internal diameter) cut from polystyrene tubes (Sterilin, Teddington, Middlesex) were packed with DHP-1 charcoal, Adsorba 150C charcoal or Amberlite XAD-7 resin. Human plasma containing 1251-labelled SEA (1 00 ng/ ml, 11 Ci/mmol) was perfused through the columns. The perfusions were performed in a scaled-down recirculating perfusion circuit for 4 h at a flow rate of 30 ml/min. Plasma was simultaneously sampled from the column inlet and outlet at different time points. The serial concentrations of SEA were determined by measurement of the 1251 radioactivity in the plasma samples in a y scintillation counter. At the end of perfusion, the columns were washed thoroughly with saline and samples of the adsorbents were counted to determine directly the amount of the substance bound to the adsorbent.
Results
Intravenous bolus injection of 250pg of SEA/kg body weight was associated with an immediate peak and rapid decline in blood concentrations of SEA ( fig.  1 ). The elimination consisted of two exponential components : an initial fast one with an average halflife of c. 3 min and a second slower one with a half-life c. 2 h. To determine whether the radioactivity detected in blood was associated with SEA, plasma samples obtained 30min after injection of the dose were ultrafiltered; < 4 % of the radioactivity was ultrafiltrable through a PM 10 membrane, indicating that most of the radioactivity in blood was still associated with SEA. Measurement of the time course of the distribution of tissue radioactivity within different tissues following the i.v. injection of 1251-labelled SEA showed that the greatest concentration of radioactivity/g wet tissue weight was found in the kidney at all time points (table  I) . Comparison of the concentration of SEA in tissue (uncorrected for blood contamination) with the concentration of SEA in blood at 30 and 120 rnin showed that SEA was at significantly higher concentrations in the kidney and spleen than in blood. The concentrations in other tissues and organs (liver, lung and muscle) were equal to or less than that in blood. On a whole organ basis, at 5 min, the liver accounted for 16 YO of the injected dose of radioactivity, kidney 8 YO and spleen 1 YO, at 30 min liver 8 YO, kidney 36 O h and spleen 2 YO, and at 120 rnin liver 6 %, kidney 20 YO and spleen 2 %. A large amount of 1251-labelled SEA was observed in urine at 30 and 120min. Ultrafiltration with a PM 10 membrane showed that > 70% of radioactivity excreted in the urine appeared to be still associated with SEA. Significant amounts of 1251-labelled SEA were also found in the duodenum at 2 h, which indicates the possibility that 1251-SEA was excreted into bile.
Efects of adsorbents on removal of SEA All adsorbents tested except for the polymyxin matrix adsorbed SEA. The polymyxin matrix, which has a specific affinity for LPS, did not bind any SEA from either PBS solution or human plasma. For the other adsorbents, a higher affinity for adsorption of SEA from PBS solution was found than from human plasma ( figs. 2a and 2b) . Comparing the binding abilities of the different adsorbents for SEA, the rank order of amount bound/g of dry adsorbent in PBS solution was: DHP-1 charcoal > Amberlite XAD-7 resin > Dowex-1 resin > Adsorba 150C charcoal. With plasma, DHP-1 charcoal, Amberlite XAD-7 resin and Dowex-1 resin adsorbed similar amounts of SEA. During 4 h in-vitro perfusion of human plasma through the adsorbent columns, DHP-1 charcoal removed 50% of the initial amount of SEA, Adsorba 150C charcoal removed 8-1 % of SEA and Amberlite XAD-7 resin removed 323% of SEA (fig. 3) . When the binding capacities were determined directly from the amount of radioactivity bound to the adsorbents and expressed as the amount/g dry weight (table 11), Table I Amberlite XAD-7 resin was better than DHP-1 charcoal. This reflected the lower dry weight of resin than charcoal in the column.
biphasic clearance is characteristic of the pharmacokinetic behaviour of many 21 reflecting first the rapid tissue uptake of SEA followed by the catabolism and excretion of SEA. Initially, 1251-labelled SEA disappeared very rapidly from blood, having an average half-life of 3 min, which is in agreement with reports that radio-iodinated SEB exhibited a half disappearance time of 2-4min in rats22 and 5-9 min in monkeys. 
Discussion
This study has demonstrated that after i.v. injection of SEA the clearance from the vascular compartment is characterised by two markedly different phases. This lowing i.v. bolus injection of 100mg of TSST-1. Examination of tissues containing lz5I-SEA revealed that the kidney was the most important site of accumulation of SEA and that SEA was excreted mainly into urine, with some excretion into bile.
Normann et showed that SEB was filtered easily by the glomerulus and was then rapidly and completely re-absorbed from the tubular urine by the cells of the proximal renal tubule. The importance of the kidney in removing these toxins from the blood has been demonstrated further by the finding that SEB disappeared from the blood at a slower rate when studies were conducted in nephrectomised monkeys or rats. 25 The kidney has been shown previously to be an important site of accumulation and catabolism of other proteins including TNF-a,'l IFN-cx,~~ IFN-Y,'~ and insulin. 28 On the other hand, it has been reported that LPS (endotoxin) derived from gram-negative bacteria is taken up by the liver immediately after i.v. injection and is concentrated primarily in the Kupffer cells.29 However, this is probably because the molecular size of LPS (c. lo6 da) is too great for renal elimination.
Protection against the effects of staphylococcal enterotoxins in vivo can be provided by induction of an antibody response or by passive transfer of antibodies, although antibody protection could be overwhelmed by massive release of enterot~xins.~~ As an alternative approach to this problem, direct removal of the toxins from the circulation may be of potential therapeutic value. Activated charcoal and Amberlite resin have been shown to have a large capacity for removing endogenous and exogenous toxins and have been used previously for clinical treatment of fulminant hepatic failure without serious adverse effect^.^' The differences between binding of the various adsorbents in PBS solution and plasma indicate that SEA interacts with components of plasma. The in-vitro plasma perfusion experiments with small columns containing either charcoal or resin demonstrated that polyhemacoated activated charcoal and uncharged resin could remove a significant amount of SEA from human plasma. Use of these non-specific adsorbents also has the advantage that they remove a range of cytokines such as TNF-a, IFN-y, interleukin (1L)-1 and IL-6 at the same time,31 some of which can be induced by staphylococcal enterotoxins. If the columns were scaled up for clinical use, it would thus be possible to remove both SEA and the inflammatory mediators released in response to SEA at the same time.
